Novartis announced the launch of a mobile research study called Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS)-a mobile research study for people with multiple sclerosis (MS)-that collects data through the participants’ smartphone, eliminating the need for clinic visits. The study is designed to gather sensor-based data from physical tasks and symptoms.
The study aims to expand understanding of the daily challenges patients with MS can have and to uncover new potential capacities of treatment effectiveness through real-time data collection from participants in their everyday life. Researchers will use the participants’ data to understand what it is like to live with MS.
The elevateMS study was developed in partnership with Sage Bionetworks and uses a mobile application that was built on the Apple ResearchKit platform. The platform allows participants to contribute from home or on the go, and allow researchers to collect data in the participant’s everyday life. The mobile app was designed with input from patients, neurologists, and advocates. To download the app and enroll in the study, click here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.